Klinische Studien zu onkologischen Erkrankungen im Bereich Oberer GI-Trakt am CCCC Berlin – unter anderem Adenokarzinom, gastric-gastroesophageal junction (GEJ) cancer und Plattenepithelkarzinom.
A Randomized, Phase ? Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric… DE ↗
Phase III · Status: active · gastric-gastroesophageal junction (GEJ) cancer
A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab orNivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plusFluoropyrimidine in Subjects with Previously… DE ↗
A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric,… DE ↗
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu ) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-line… DE ↗
Vorhersage der Hämatotoxizität und nicht-hämatologischen Toxizität von perioperativen Systemtherapien sowie weiteren klinischen Outcome-Parametern bei Patienten mit lokal fortgeschrittenem Karzinom des Magens oder… DE ↗
Effect of chemotherapy alone vs. chemotherapy followed by surgical resection onsurvival and quality of life in patients with limited-metastatic adenocarcinoma of thestomach or esophagogastric junction – a phase III… DE ↗
Mangire = Modified additional Nutrition in Gastro-Intestinal Adenocarcinoma prior Resection – Evaluation - Studie zur Evaluation der biologischen Effekte von drei verschiedenen Ernährungsszenarien bei Patient*innen mit… DE ↗
Protocol Title: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment… DE ↗
Protocol Title: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer naive to PD-1/PD-L1 Treatment… DE ↗
POLESTAR – Phase II trial of pembrolizumab and olaparib preceded by short-term chemotherapy and pembrolizumab in Her-2 negative esophagogastric adenocarcinoma DE ↗
Phase II Study of Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients DE ↗
Ihre Situation ist nicht dabei?
Auch wenn hier keine passende Studie gelistet ist, kann eine molekulare Diagnostik neue Behandlungsoptionen aufzeigen. Sprechen Sie unsere Cancer Hotline an.